Nuclear factor-κB as a therapeutic target in critical care medicine

Basilia Zingarelli, Maeve Sheehan, Hector R. Wong

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Nuclear factor-κB is a transcriptional factor required for the gene expression of many inflammatory mediators. Nuclear factor-κB activation requires removal and degradation of its inhibitor κB, an event that occurs after phosphorylation of inhibitor κB by a complex of inhibitor κB kinases. These events allow nuclear factor-κB to translocate into the nucleus, where it binds to κB elements and initiates transcription. Inappropriate and prolonged activation of nuclear factor-κB has been linked to several diseases associated with inflammatory events, including septic shock, acute respiratory distress syndrome, ischemia, and reperfusion injury. Thus, the key role of nuclear factor-κB in regulating inflammation makes this factor a therapeutic target for reducing tissue and organ damage. Regulation and control of nuclear factor-κB can be achieved by gene modification strategies or by pharmacologic inhibition of the key components of the cascade that leads to nuclear factor-κB activation. The purpose of our review is to describe these novel therapeutic approaches and their potential efficacy.

Original languageEnglish (US)
JournalCritical Care Medicine
Volume31
Issue number1 SUPPL.
StatePublished - Jan 1 2003

Fingerprint

Critical Care
Medicine
Adult Respiratory Distress Syndrome
Septic Shock
Reperfusion Injury
Phosphotransferases
Phosphorylation
Inflammation
Gene Expression
Therapeutics
Genes

Keywords

  • Gene therapy
  • IκB kinases
  • Inflammation
  • Inhibitor κBα
  • Nuclear factor-κB inhibitors
  • Sepsis

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Nuclear factor-κB as a therapeutic target in critical care medicine. / Zingarelli, Basilia; Sheehan, Maeve; Wong, Hector R.

In: Critical Care Medicine, Vol. 31, No. 1 SUPPL., 01.01.2003.

Research output: Contribution to journalArticle

Zingarelli, Basilia ; Sheehan, Maeve ; Wong, Hector R. / Nuclear factor-κB as a therapeutic target in critical care medicine. In: Critical Care Medicine. 2003 ; Vol. 31, No. 1 SUPPL.
@article{efdf2c1ba3cd445cabc83e717b0764ea,
title = "Nuclear factor-κB as a therapeutic target in critical care medicine",
abstract = "Nuclear factor-κB is a transcriptional factor required for the gene expression of many inflammatory mediators. Nuclear factor-κB activation requires removal and degradation of its inhibitor κB, an event that occurs after phosphorylation of inhibitor κB by a complex of inhibitor κB kinases. These events allow nuclear factor-κB to translocate into the nucleus, where it binds to κB elements and initiates transcription. Inappropriate and prolonged activation of nuclear factor-κB has been linked to several diseases associated with inflammatory events, including septic shock, acute respiratory distress syndrome, ischemia, and reperfusion injury. Thus, the key role of nuclear factor-κB in regulating inflammation makes this factor a therapeutic target for reducing tissue and organ damage. Regulation and control of nuclear factor-κB can be achieved by gene modification strategies or by pharmacologic inhibition of the key components of the cascade that leads to nuclear factor-κB activation. The purpose of our review is to describe these novel therapeutic approaches and their potential efficacy.",
keywords = "Gene therapy, IκB kinases, Inflammation, Inhibitor κBα, Nuclear factor-κB inhibitors, Sepsis",
author = "Basilia Zingarelli and Maeve Sheehan and Wong, {Hector R.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "31",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Nuclear factor-κB as a therapeutic target in critical care medicine

AU - Zingarelli, Basilia

AU - Sheehan, Maeve

AU - Wong, Hector R.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Nuclear factor-κB is a transcriptional factor required for the gene expression of many inflammatory mediators. Nuclear factor-κB activation requires removal and degradation of its inhibitor κB, an event that occurs after phosphorylation of inhibitor κB by a complex of inhibitor κB kinases. These events allow nuclear factor-κB to translocate into the nucleus, where it binds to κB elements and initiates transcription. Inappropriate and prolonged activation of nuclear factor-κB has been linked to several diseases associated with inflammatory events, including septic shock, acute respiratory distress syndrome, ischemia, and reperfusion injury. Thus, the key role of nuclear factor-κB in regulating inflammation makes this factor a therapeutic target for reducing tissue and organ damage. Regulation and control of nuclear factor-κB can be achieved by gene modification strategies or by pharmacologic inhibition of the key components of the cascade that leads to nuclear factor-κB activation. The purpose of our review is to describe these novel therapeutic approaches and their potential efficacy.

AB - Nuclear factor-κB is a transcriptional factor required for the gene expression of many inflammatory mediators. Nuclear factor-κB activation requires removal and degradation of its inhibitor κB, an event that occurs after phosphorylation of inhibitor κB by a complex of inhibitor κB kinases. These events allow nuclear factor-κB to translocate into the nucleus, where it binds to κB elements and initiates transcription. Inappropriate and prolonged activation of nuclear factor-κB has been linked to several diseases associated with inflammatory events, including septic shock, acute respiratory distress syndrome, ischemia, and reperfusion injury. Thus, the key role of nuclear factor-κB in regulating inflammation makes this factor a therapeutic target for reducing tissue and organ damage. Regulation and control of nuclear factor-κB can be achieved by gene modification strategies or by pharmacologic inhibition of the key components of the cascade that leads to nuclear factor-κB activation. The purpose of our review is to describe these novel therapeutic approaches and their potential efficacy.

KW - Gene therapy

KW - IκB kinases

KW - Inflammation

KW - Inhibitor κBα

KW - Nuclear factor-κB inhibitors

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=0037247748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037247748&partnerID=8YFLogxK

M3 - Article

C2 - 12544984

AN - SCOPUS:0037247748

VL - 31

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 1 SUPPL.

ER -